evalu
associ
chang
incid
aki
diseas
clinic
outcom
use
logist
regress
model
result
total
patient
aki
without
aki
includ
analysi
compar
patient
without
aki
aki
patient
older
predominantli
male
like
present
hypoxia
preexist
hypertens
cerebrovascular
diseas
moreov
aki
patient
higher
level
white
blood
cell
ddimer
aspart
aminotransferas
total
bilirubin
creatin
kinas
lactat
dehydrogenas
procalcitonin
creactiv
protein
higher
preval
hyperkalemia
lower
lymphocyt
count
higher
chest
comput
tomograph
score
incid
stage
aki
incid
stage
aki
patient
aki
substanti
higher
mortal
conclus
aki
import
complic
older
age
male
multipl
preexist
comorbid
lymphopenia
increas
infect
indic
elev
ddimer
impair
heart
liver
function
risk
factor
aki
aki
patient
progress
stage
aki
higher
mortal
rate
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
background
decemb
cluster
sever
pneumonia
case
unknown
caus
emerg
wuhan
china
clinic
present
greatli
resembl
viral
pneumonia
deep
sequenc
analysi
lower
respiratori
tract
sampl
indic
novel
coronaviru
name
novel
coronaviru
name
februari
total
number
patient
risen
sharpli
confirm
case
death
case
http
number
critic
ill
patient
high
clinic
spectrum
pneumonia
rang
nonsever
sever
case
previou
studi
describ
gener
epidemiolog
find
clinic
present
clinic
outcom
patient
pneumonia
note
latest
data
suggest
kidney
vulner
organ
patient
besid
lung
evid
acut
kidney
injuri
aki
fatal
case
howev
current
publish
inform
character
aki
risk
factor
outcom
patient
studi
investig
aki
patient
admit
hankou
hospit
wuhan
confirm
pneumonia
determin
factor
associ
aki
patient
hospit
order
identifi
factor
use
earli
identif
individu
risk
develop
aki
provid
intens
care
treatment
therebi
reduc
mortal
morbid
associ
aki
patient
singlecent
retrospect
observ
studi
conduct
hankou
hospit
wuhan
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
china
hospit
design
treat
pneumonia
patient
criteria
suspect
confirm
case
base
criteria
previous
establish
patient
met
criteria
includ
studi
patient
younger
year
undergon
renal
replac
therapi
rrt
admiss
whose
entir
stay
last
less
hour
exclud
analysi
primari
variabl
interest
incid
aki
secondari
outcom
variabl
includ
mortal
calcul
day
admiss
length
hospit
stay
studi
approv
nation
health
commiss
china
ethic
commiss
hankou
hospit
ethic
commiss
hankou
hospit
waiv
requir
obtain
inform
consent
obtain
epidemiolog
demograph
clinic
laboratori
manag
outcom
data
patient
medic
record
use
standard
data
collect
form
clinic
outcom
follow
march
analyz
relationship
aki
stage
clinic
outcom
minimum
followup
time
day
requir
includ
followup
patient
discharg
march
data
miss
record
clarif
need
research
also
directli
commun
patient
famili
ascertain
epidemiolog
symptom
data
data
check
two
physician
gx
fz
initi
investig
includ
complet
blood
count
coagul
profil
serum
biochem
test
includ
renal
liver
function
creatin
kinas
lactat
dehydrogenas
ldh
electrolyt
common
respiratori
pathogen
descript
treatment
procedur
measur
publish
previous
patient
chest
comput
tomographi
ct
scan
admiss
ct
imag
review
two
fellowshiptrain
cardiothorac
radiologist
gx
fw
approxim
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
year
experi
use
electron
medic
record
system
hankou
hospit
imag
review
independ
final
decis
reach
consensu
case
disagr
two
primari
radiologist
interpret
third
fellowshiptrain
cardiothorac
radiologist
year
experi
hl
adjud
final
decis
neg
control
case
examin
blind
occur
radiologist
evalu
initi
ct
scan
assign
quantit
score
characterist
use
recent
publish
score
system
total
ct
score
sum
lung
involv
lobe
score
lobe
rang
none
maximum
determin
acut
kidney
injuri
aki
identifi
classifi
basi
highest
serum
creatinin
cr
level
accord
kidney
diseas
improv
global
outcom
kdigo
definit
stage
system
howev
urin
output
routin
monitor
hospit
render
approach
infeas
thu
use
increas
creatinin
alon
diagnosi
stage
aki
besid
miss
baselin
serum
creatinin
measur
exist
patient
admiss
two
altern
method
use
estim
baselin
creatinin
valu
order
make
diagnosi
aki
averag
serum
creatinin
method
use
nonaki
patient
data
calcul
averag
serum
creatinin
valu
base
age
sex
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
stage
increas
serum
creatinin
time
baselin
increas
serum
creatinin
moll
initi
renal
replac
therapi
statist
analysi
perform
use
spss
softwar
window
version
ibm
corp
armonk
ny
usa
descript
analys
perform
demograph
clinic
laboratori
data
bivari
analys
use
assess
associ
aki
statu
differ
paramet
interest
continu
data
white
blood
cell
count
convert
categor
variabl
normal
low
high
level
multivari
analysi
perform
due
small
sampl
size
odd
ratio
obtain
logist
regress
use
measur
strength
associ
factor
aki
p
valu
consid
indic
statist
signific
date
onset
symptom
use
start
date
conduct
death
certif
search
medic
record
determin
whether
patient
aliv
discharg
die
subsequ
includ
data
analysi
applic
studi
period
total
patient
admit
met
case
definit
clinic
confirm
infect
inclus
criteria
characterist
patient
admiss
overal
accord
aki
statu
shown
tabl
patient
aki
patient
without
aki
incid
aki
accord
averag
serum
creatinin
method
compar
patient
without
aki
patient
aki
like
male
significantli
older
like
underli
comorbid
includ
chronic
renal
insuffici
hypertens
cerebrovascular
diseas
patient
aki
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
tend
sever
pneumonia
like
hypoxia
tachypnea
tabl
show
result
laboratori
test
perform
admiss
accord
aki
statu
compar
patient
without
aki
patient
aki
higher
white
blood
cell
neutrophil
count
higher
level
ddimer
aspart
aminotransferas
total
bilirubin
creatin
kinas
ldh
procalcitonin
pct
creactiv
protein
crp
higher
preval
hyperkalemia
compar
patient
without
aki
patient
aki
lower
lymphocyt
count
lower
serum
albumin
nucleic
acid
assay
respiratori
pathogen
antibodi
detect
patient
respiratori
syncyti
viru
ab
patient
mycoplasma
pneumonia
patient
chlamydophila
pneumonia
coinfect
none
patient
respiratori
coinfect
develop
aki
tabl
seri
typic
ct
imag
patient
initi
onset
symptom
recoveri
shown
fig
accord
chest
ct
aki
patient
significantli
higher
median
ct
score
nonaki
patient
tabl
patient
studi
discharg
march
date
followup
censor
mortal
tabl
incid
stage
stage
aki
respect
aki
stage
relat
clinic
endpoint
patient
comparison
outcom
accord
aki
statu
stage
found
compar
nonaki
patient
stage
stage
aki
significantli
lower
discharg
rate
nonaki
aki
stage
aki
stage
respect
significantli
higher
mortal
rate
nonaki
aki
stage
aki
stage
respect
median
length
hospit
day
nonaki
aki
stage
aki
stage
patient
respect
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
recent
semin
work
indic
use
angiotensin
convert
enzym
ii
cell
entri
receptor
cellular
mechan
ident
sarscov
addit
gainoffunct
experi
found
could
use
wildtyp
coronaviru
bat
origin
gain
entri
cell
exclus
express
respiratori
organ
also
human
tissu
note
express
almost
higher
kidney
tissu
importantli
nucleic
acid
found
urin
patient
togeth
multipl
line
evid
indic
kidney
impair
may
one
major
caus
morbid
among
patient
may
contribut
multiorgan
failur
death
studi
investig
incid
aki
risk
factor
aki
patient
studi
includ
patient
admit
hankou
hospit
wuhan
februari
march
incid
aki
among
patient
studi
substanti
higher
overal
incid
report
previou
studi
compar
critic
ill
patient
hospit
ill
follow
reason
may
explain
higher
incid
aki
observ
studi
compar
previou
studi
first
patient
admit
hospit
sever
diseas
time
admiss
patient
sever
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
diseas
although
mani
patient
low
puls
oxygen
satur
admit
hospit
symptom
dyspnea
tend
mild
reason
might
patient
condit
gradual
deterior
bodi
adapt
compens
degre
high
ct
score
rapid
deterior
mani
patient
admiss
also
provid
evid
sever
diseas
among
patient
studi
second
method
use
diagnos
stage
aki
might
overestim
incid
sever
due
outbreak
shortag
medic
resourc
mani
patient
baselin
serum
creatinin
test
prior
admiss
creatinin
test
previou
year
therefor
could
estim
baselin
serum
creatinin
patient
accord
patient
sex
weight
medic
histori
relat
paramet
incid
aki
determin
base
baselin
valu
serum
creatinin
valu
within
day
admiss
order
reduc
bia
estim
baselin
valu
two
method
includ
averag
serum
creatinin
method
egfr
method
use
comparison
aki
incid
rate
accord
averag
serum
creatinin
method
accord
method
supplement
tabl
calcul
valu
baselin
serum
creatinin
estim
method
significantli
differ
patient
baselin
serum
creatinin
result
avail
imprecis
inaccuraci
estim
baselin
valu
serum
creatinin
might
caus
overestim
incid
aki
studi
howev
overestim
incid
aki
may
directli
affect
investig
aki
risk
factor
found
compar
nonaki
patient
older
age
multipl
preexist
comorbid
increas
white
blood
cell
count
low
lymphocyt
count
increas
level
pct
crp
risk
factor
aki
preval
sever
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
preexist
comorbid
consid
includ
chronic
lung
diseas
diabet
mellitu
differ
significantli
patient
without
aki
although
might
due
rel
small
number
case
aki
studi
lymphopenia
indic
decreas
immun
might
occur
patient
increas
level
pct
crp
suggest
patient
may
secondari
bacteri
infect
caus
excess
inflammatori
respons
unfortun
conduct
bacteri
fungal
cultur
patient
respiratori
coinfect
detect
pcr
shortag
medic
staff
unabl
test
patient
inflammatori
factor
profil
local
hospit
inflammatori
factor
test
kit
previou
studi
shown
patient
significantli
increas
ddimer
level
multipl
organ
damag
electrolyt
disturb
studi
reveal
abnorm
pronounc
patient
aki
result
suggest
patient
may
experi
sever
hypoxia
result
aggrav
multipl
organ
damag
overlook
might
also
directli
attack
multipl
organ
especi
kidney
occurr
develop
aki
often
lead
imbal
blood
volum
electrolyt
accumul
metabolit
aggrav
multipl
organ
dysfunct
creat
viciou
cycl
major
patient
stage
aki
recov
discharg
progress
stage
aki
extrem
high
mortal
rate
underli
reason
might
due
limit
treatment
condit
urgent
breakout
period
countri
studi
result
suggest
earli
intervent
occurr
aki
import
continu
renal
replac
consid
help
allevi
progress
aki
survey
includ
clinic
confirm
case
suspect
case
also
known
clinic
confirm
case
present
exact
epidemiolog
histori
mani
patient
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
chang
mild
sever
home
quarantin
due
long
observ
time
mani
patient
show
neg
rtpcr
assay
hospit
fact
still
suspect
case
turn
posit
two
neg
rtpcr
result
discharg
recogn
laboratoryconfirm
case
addit
laboratori
test
infectionrel
indic
pct
crp
common
respiratori
pathogen
nucleic
acid
determin
ct
scan
also
help
us
differenti
pneumonia
research
follow
shortcom
first
due
larg
number
patient
popul
shortag
medic
staff
equip
perform
blood
ga
analysi
blood
lactat
measur
patient
instead
base
patient
main
complaint
puls
oxygen
satur
monitor
ct
indirectli
judg
oxygen
second
explor
impact
treatment
aki
treatment
base
standard
procedur
antivir
drug
antibacteri
drug
hormon
littl
effect
renal
function
third
exclud
patient
chronic
renal
insuffici
five
patient
chronic
renal
insuffici
case
aki
group
nonaki
group
patient
relat
hypertens
case
diabet
case
admiss
show
normal
creatinin
level
past
year
fourth
due
urgent
collat
data
shorter
followup
time
patient
shortest
hospit
stay
patient
day
may
interfer
final
prognosi
judgment
lead
failur
analyz
surviv
time
fifth
analyz
comorbid
patient
shock
adult
respiratori
distress
syndrom
ard
focu
analyz
risk
factor
aki
present
admiss
order
provid
evid
develop
prevent
treatment
guidelin
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
kidney
primari
target
organ
incid
aki
high
patient
hospit
deterior
kidney
function
aggrav
organ
damag
identifi
risk
factor
aki
patient
includ
older
age
sever
pneumonia
preexist
cardiovascular
renal
diseas
although
incid
stage
aki
critic
ill
patient
high
recov
howev
patient
progress
stage
aki
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
patient
initi
ct
scan
evalu
quantit
score
assign
base
characterist
report
recent
publish
literatur
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
data
n
median
iqr
p
valu
compar
aki
patient
nonaki
patient
p
consid
statist
signific
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
